CalciMedica, Inc.
Close on Oct 19, 2026
- Market cap
- $17.44M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | $-0.45 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | $0.30 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.52 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | $-0.40 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | After market close | – | $-0.36 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | After market close | – | $0.01 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 22, 2024 | Before market open | – | – | – |
Press releases
Announcements CalciMedica filed with the SEC
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Investor Update June 2026 Exhibit
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Secures Credit Facility for Up to $32.5 Million
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
CalciMedica Announces Proposed Public Offering of Common Stock
Results of operations · Other events · EX-99.1 to Form 8-K
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Immunologic Diseases October 2024 1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Immunologic Diseases CARPO Trial Topline Results June 27, 2024 1 Confidential
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Immunologic Diseases February 2024 1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CalciMedica Announces Private Placement of up to Approximately $55 Million
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
CalciMedica Announces Private Placement of up to Approximately $55 Million
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
Results of operations · EX-99.1 to Form 8-K
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65 th Annual ASH Meeting & Exposition
Results of operations · Other events · EX-99.1 to Form 8-K
Report of Independent Registered Public Accounting Firm
Other events · EX-99.2 to Form 8-K
CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
Results of operations · Shareholder vote results · EX-99.1 to Form 8-K
Inflammatory Diseases with High Unmet Need June 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
CalciMedica Announces Relisting on Nasdaq
Regulation FD disclosure · EX-99.1 to Form 8-K
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate
Results of operations · EX-99.1 to Form 8-K
CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent
Acquisition or disposition completed · Listing notice · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
[OPERATOR]: Ladies and gentlemen, thank you for
Other events · EX-99.1 to Form 8-K
Graybug and CalciMedica Enter into Definitive Merger Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
Graybug Vision Reports Financial Results for the Three
Results of operations · EX-99.1 to Form 8-K
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K
Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments
Results of operations · EX-99.1 to Form 8-K